In Situ Hybridization Market worth $2.8 billion by 2027
The report "In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospitals, Pharma, Biotech, CROs) – Global Forecast to 2027", is projected to reach USD 2.8 billion by 2027 from USD 1.5 billion in 2022 growing at a CAGR of 12.6%.
Browse 235 market data Tables and 31 Figures spread through 201 Pages and in-depth TOC on "In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospitals, Pharma, Biotech, CROs) – Global Forecast to 2027"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/in-situ-hybridization-market-212028829.html
Key drivers of the in situ hybridization market include rising incidence of genetic disorders and cancer, and growing awareness of companion diagnostics. However, a shortage of skilled professionals poses a significant challenge to the growth of this market.
The FISH segment dominates the in situ hybridization (ISH) market through 2020-2027.
The global in situ hybridization market is segmented into product, technology, application, end user, and region. FISH uses fluorescently labeled DNA probes to detect or confirm the presence of genes or chromosomal abnormalities. It is also used in clinical research for the prenatal diagnosis of inherited chromosomal aberrations and postnatal diagnosis of carriers of genetic diseases. FISH is considered more reliable, sensitive, and accurate as compared to IHC; moreover, this test does not require expensive equipment.
In 2021, the hospitals and diagnostic laboratories ranked first in terms of revenue in the in situ hybridization market.
Based on end users, the global in situ hybridization market is segmented into hospitals and diagnostic laboratories, academic & research institutes, contract research organizations (CROs), and pharmaceutical & biotechnology companies. In 2021, the hospitals and diagnostic laboratories segment accounted for the largest share of the in situ hybridization market, due to an increasing number of molecule-based screenings, the increasing number of specialty diagnostic tests performed in hospital laboratories, the rising number of in-house diagnostic procedures, and the rising trend of establishing in-house diagnostic capabilities in hospitals.
The Asia Pacific region is the fastest-growing region of the in situ hybridization market in 2021.
The Asia Pacific region is estimated to grow at the highest CAGR in the in situ hybridization market during the forecast period. China and India are the key revenue contributors to the Asia Pacific in situ hybridization market. Favorable government support for product approvals and the presence of major players in these countries are anticipated to drive regional market growth.
The in situ hybridization market is consolidated in nature with prominent players in the in situ hybridization market including Abbott (US), Abcam (UK), Abnova Corporation (Taiwan), Agilent Technologies, Inc. (US), Bio SB Inc. (US), Biocare Medical, LLC (US), BioCat GmbH (Germany), BioGenex Laboratories (US), Bio-Rad Laboratories (US), Bio-Techne Corporation (US), BioView (Israel), Creative Bioarray (US), Danaher (US), Enzo Biochem (US), F. Hoffmann-La Roche AG (Switzerland), GeneMed Biotechnologies Inc. (US), Merck KGaA (Germany), NeoGenomics Laboratories (US), OpGen (US), Oxford Gene Technology (UK), PerkinElmer Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific (US), and ZytoVision GmbH (Germany).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the In Situ Hybridization Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
